Clinical Trial

Trial Protocol ID MCLA-128-CL01_eNRGy *RIT*

Trial Description

A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy)

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Disease Types

Sponsor

  • Merus N.V.

ClinicalTrials.gov NCT ID

  • NCT02912949